Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaTony Mok, Masahiro Fukuoka, Yukito Ichinose et al.|New England Journal of Medicine|2009Cited by 8.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Masahiro Fukuoka, Tony Mok, Yi‐Long Wu et al.|Journal of Clinical Oncology|2011Cited by 1.6k
Interstitial Lung Disease in Japanese Patients with Lung CancerShoji Kudoh, Fredrik Nyberg, Harubumi Kato et al.|American Journal of Respiratory and Critical Care Medicine|2008Cited by 488
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung CancerRiichiroh Maruyama, Masahiro Fukuoka, Yutaka Nishiwaki et al.|Journal of Clinical Oncology|2008Cited by 365